These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15952414)

  • 41. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.
    Manasco PK; Pescovitz OH; Feuillan PP; Hench KD; Barnes KM; Jones J; Hill SC; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Aug; 67(2):368-72. PubMed ID: 3292562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis.
    Saggese G; Pasquino AM; Bertelloni S; Baroncelli GI; Battini R; Pucarelli I; Segni M; Franchi G
    Acta Paediatr; 1995 Mar; 84(3):299-304. PubMed ID: 7780252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome.
    Menke LA; Sas TC; de Muinck Keizer-Schrama SM; Zandwijken GR; de Ridder MA; Odink RJ; Jansen M; Delemarre-van de Waal HA; Stokvis-Brantsma WH; Waelkens JJ; Westerlaken C; Reeser HM; van Trotsenburg AS; Gevers EF; van Buuren S; Dejonckere PH; Hokken-Koelega AC; Otten BJ; Wit JM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1151-60. PubMed ID: 20061421
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low growth hormone levels are related to increased body mass index and do not reflect impaired growth in luteinizing hormone-releasing hormone agonist-treated children with precocious puberty.
    Kamp GA; Manasco PK; Barnes KM; Jones J; Rose SR; Hill SC; Cutler GB
    J Clin Endocrinol Metab; 1991 Feb; 72(2):301-7. PubMed ID: 1991801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
    Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
    J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial.
    Gault EJ; Cole TJ; Casey S; Hindmarsh PC; Betts P; Dunger DB; Donaldson MDC
    Arch Dis Child; 2021 Jan; 106(1):74-76. PubMed ID: 31862699
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of treatment with GH alone or in combination with LHRH analog on bone mineral density in pubertal GH-deficient patients.
    Mericq V; Gajardo H; Eggers M; Avila A; Cassorla F
    J Clin Endocrinol Metab; 2002 Jan; 87(1):84-9. PubMed ID: 11788628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxandrolone in constitutional delay of growth: analysis of the growth patterns up to final stature.
    Bassi F; Neri AS; Gheri RG; Cheli D; Serio M
    J Endocrinol Invest; 1993 Feb; 16(2):133-7. PubMed ID: 8463549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome.
    Cacciari E; Mazzanti L
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4510-5. PubMed ID: 10599710
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of peripubertal children after renal transplantation (RTX) with recombinant human growth hormone: auxological data and effects on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during 24 months.
    Riedl S; Lebl J; Kluge M; Kreisinger J; Simková E; Kohlhauser C; Balzar E; Frisch H
    J Pediatr Endocrinol Metab; 1998; 11(6):713-8. PubMed ID: 9829225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Effect of gonadotropin-releasing hormone analog combined with stanazolol on final height in girls with idiopathic central precocious puberty and apparent decrease of linear growth].
    Li YH; Zhu SY; Ma HM; Su Z; Chen HS; Chen QL; Gu YF; Du ML
    Zhonghua Er Ke Za Zhi; 2013 Nov; 51(11):807-12. PubMed ID: 24484553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.
    Haeusler G; Schmitt K; Blümel P; Plöchl E; Waldhör T; Frisch H
    Acta Paediatr; 1996 Dec; 85(12):1408-14. PubMed ID: 9001649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oxandrolone in girls with Turner's syndrome. A pair-matched controlled study up to final height.
    Joss E; Zuppinger K
    Acta Paediatr Scand; 1984 Sep; 73(5):674-9. PubMed ID: 6385611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome).
    Savage MO; Blum WF; Ranke MB; Postel-Vinay MC; Cotterill AM; Hall K; Chatelain PG; Preece MA; Rosenfeld RG
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1465-71. PubMed ID: 7505286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
    Zucchini S; Pirazzoli P; Baronio F; Gennari M; Bal MO; Balsamo A; Gualandi S; Cicognani A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4271-6. PubMed ID: 16912138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of growth hormone and gonadotropin releasing hormone agonist in addition to L-thyroxine to attain normal adult height in two patients with severe Hashimoto's thyroiditis.
    Quintos JB; Salas M
    J Pediatr Endocrinol Metab; 2005 May; 18(5):515-21. PubMed ID: 15921183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.
    Loche S; Pintor C; Cambiaso P; Lampis A; Carta D; Corda R; Cappa M
    J Endocrinol Invest; 1991 Oct; 14(9):747-50. PubMed ID: 1761810
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oxandrolone increases final height in Turner syndrome.
    Crock P; Werther GA; Wettenhall HN
    J Paediatr Child Health; 1990 Aug; 26(4):221-4. PubMed ID: 2257185
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich-Turner syndrome.
    Schmitt K; Häusler G; Blümel P; Plöchl E; Waldhör T; Frisch H
    Eur J Pediatr; 1997 Feb; 156(2):99-103. PubMed ID: 9039510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.